Sarah Cannon Research Institute (SCRI) - Articles and news items

Lilly and SCRI team up to develop investigational oncology therapy

Industry news / 17 June 2015 /

Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+